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Abstract: Chronic obstructive pulmonary disease (COPD) is a complex disease with 
multifactorial background, based on the interaction of environmental and genetic factors. 
Environmental factors are clearly related to the development of the disease. However, family 
and twin studies suggested genetics factors to be one of the important determinants for the 
development of COPD. Different approaches have been used to identify genes of interest. 
Genomewide linkage analysis found areas of interest on different chromosomes, with some 
genes located in this regions being identiﬁ  ed and replicated as susceptibility genes. Numerous 
of candidate genes that could be linked to disease pathogenesis have been implicated in COPD 
genetics. However, the candidate gene approach is often limited by inconsistent results in other 
study populations. Recently, a combination of different methods is used giving more evidence 
for some candidate genes, including TGFß-1, Surfactant, SERPINE2 and microsomal epoxide 
hydrolase. In the future ongoing exact phenotype deﬁ  nition, combination of several approaches, 
genome-wide association studies and animal model genetics will lead to new insights into the 
genetics of COPD, with epigenetic factors needs to be further investigated and considered in 
concert with genetic ﬁ  ndings.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major health problem as it causes 
increasing mortality and morbidity in all industrial countries (Pauwels et al 2001; Hurd 
2005). Progressive irreversible airﬂ  ow limitation is the central pathogenetic aspect in 
COPD. However, the disease is not only determined by pulmonary function, but by 
airway tissue inﬂ  ammation, airway remodeling and systemic consequences.
The most important risk factor in the etiopathogenesis of COPD is cigarette 
smoking. Nevertheless, only 10%–20% of all heavy cigarette smokers develop 
COPD (Fletcher 1976; Redline et al 1987; Sherrill 1990; Global Initiative for Chronic 
Obstuctive Lung Disease 2001; Mannino 2002, 2003; Mannino et al 2003). There 
is strong evidence for a relationship between decline in lung function and smoking 
behavior. However, smoking account only for about 15% of lung function variability 
(Beck et al 1981). These observations demonstrate that next to smoking other fac-
tors seems to be of importance for the development of the disease. Epidemiological 
data suggest genetics to be one of those factors, as COPD is known to aggregate in 
families (Larson et al 1970; Tager et al 1976; Lebowitz et al 1984), with a stronger 
correlation between parents and children or siblings than between spouses (Higgins 
and Keller 1975; Tager et al 1976; Kauffmann et al 1989). Twin (Redline 1987, 1990) 
and segregation studies (Givelber 1998) provide evidence that genetic predisposition 
plays a role in COPD (Hubert et al 1982; Astemborski et al 1985; Redline et al 1987; 
Rybicki et al 1990; Chen et al 1996; Givelber et al 1998) and had indicated that the 
genetic background of COPD is composed of several genes with small effects, rather 
than a single major gene. Despite the general fact that genetic studies in COPD are International Journal of COPD 2007:2(4) 542
Seifart and Plagens
difﬁ  cult to conduct due to the variating phenotypes subsume 
under the disease deﬁ  nition, there are different possible 
approaches to analyze genetic factors of importance. Basic 
genetic studies include family and twin studies, as well as 
segregation studies. In linkage and positional cloning stud-
ies susceptibility genes could be identiﬁ  ed on the basis of 
their chromosomal position. The genetic bases of COPD 
might also be investigated, similar to other diseases with 
complex and multifactorial etiology, by the analysis of can-
didate genes – genes that are postulated to play an important 
role in disease pathogenesis. This review will focus on the 
candidate gene approach after giving an short overview 
about the results of linkage studies.
Linkage studies
The genetic bases of lung function and/or COPD had been 
investigated using linkage or positional cloning studies. 
Linkage studies investigate haplotypes, or short segments 
of the genome, conserved between generations by virtue of 
their size. If a haplotype is found that is passed down along 
with a disease through a family, it could be speculated that 
there is a gene within or close to that may have an effect on 
the disease. To perform linkage analysis phenotypic data 
and DNA from affected families are needed at least from 
two generations. From each family all members typed for 
genetic markers throughout the whole genome, following by 
determination whether any of these markers are inherited with 
the disease more often than predicted by chance. In case of a 
positive correlation the disease is “linked” to that marker on 
a distinct chromosome. This method provides the possibil-
ity to identify novel genes, because linkage of the disease 
to a genetic marker depends only on the close proximity of 
that marker with the susceptibility gene, independent of a 
potential functional correlation. But these studies are not 
easy to conduct in COPD since the disease has a late onset 
in life and family members that are needed for analysis may 
no longer be alive.
Genomewide linkage analysis exploring genetic linkage to 
lung function was performed in several studies. The genetic 
determinants of FEV1, FVC and FEV1/FVC ratio had been 
studied in healthy subjects and patients with COPD. Two 
population- and one disease-based linkage analysis found 
strongest evidence of linkage to FEV1/FVC ratio (chromosome 
4 [logarithm of the odds favoring genetic linkage (LOD) 3,5], 
chromosome 2q [LOD 4,12], and chromosome 2 [LOD 4,12]) 
(Joost et al 2002; Silverman et al 2002; Wilk et al 2003; DeMeo 
et al 2004). In healthy young adults of the Framingham Heart 
cohort a genome-wide scan of 330 families with over 1500 
members found that loci strongly inﬂ  uencing FEV1 occurred on 
chromosome 6 [LOD score 2,4] and for FVC on chromosome 
21 [LOD 2,6] (Joost et al 2002). In another study including 
more than 2100 healthy subjects from 391 families who partici-
pated in the National Heart, Lung and Blood Institute (NHLBI) 
Family Heart Study FEV1 and FVC were suggestively linked to 
regions of chromosome 18 [LOD 2,4]/ [LOD 1.5 / 2,4] (Wilk 
et al 2003). Interestingly, in a genomewide screen for pulmo-
nary function in families of patients with asthma signiﬁ  cant 
evidence for linkage of pre- and postbronchodilator FEV1%VC 
was obtained for chromosome 2q (2q32, LOD 4,9/6.03) 
(Postma 2005). The Boston Early-onset (BEO) studies fami-
lies with subjects suffering from severe early-onset COPD. 
A genome-wide scan of 585 family members participating 
in this study showed the highest LOD score for FEV1 was 
1.53 on chromosome 12 and 2.05 for FVC on chromosome 1 
(Silverman et al 2002). If only smoking subjects were included, 
evidence for linkage to FEV1/FVC ratio was increased on 
chromosome 2 (LOD 4.13) and for FEV1 on chromosome 
12p (LOD 3,26). Evidence for linkage of chronic bronchitis 
or airway obstruction was shown for chromosome 22 (LOD 
2.08)/12p (LOD 2,13), respectively. Table 1 summarizes the 
main results of these linkage studies.
Instance areas of interest from linkage studies included 
SERPINE2 and IL-8 as potential candidate genes (both on 
chromosome 2), as well as microsomal GST1 and TGFß genes 
(chromosome 12 and 19) in terms of the severity of pulmonary 
function in COPD. However, there is no direct evidence for 
the signiﬁ  cance of linkage studies for COPD pathogenesis.
Candidate genes – association 
studies
Variations, or polymorphism, within genes are classiﬁ  ed 
by means of a change in DNA alone or effect on the pro-
tein it codes for. Sigle nucleotide polymorphism consists 
of a sigle base change are the most common in the human 
genome. They could either be functional or not. Candidate 
gene analysis compare the frequency of gene variations or 
polymorphism in groups with the given disease and control 
individuals. In diseases with complex and multifactorial 
etiology, such as COPD, the use of candidate genes may 
help to identify genetic factors of potential importance. In 
the candidate gene approach genes are tested directly for 
their involvement in disease process. Genes that are selected 
are those that could be postulated to be functional related 
to the disease. The candidate gene approach is limited on 
the one hand by the fact that only known genes can be 
examined, controls and patients are difﬁ  cult to match and International Journal of COPD 2007:2(4) 543
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the need of a very exact phenotype deﬁ  nition. On the other 
hand COPD is a multifactorial disease that is inﬂ  uenced 
by genetic as well as environmental factors resulting in a 
complex genotype-environment interaction. However, a 
reasonable large number of successful association studies 
had analyzed candidate genes selected on the base of COPD 
pathophysiology.
COPD is characterized by a progressive decline in lung 
function due to increasing irreversible airway obstruction. This 
results from ongoing chronic airway inﬂ  ammation and loss 
of lung elastic recoil due to parenchymal destruction. Many 
inﬂ  ammatory cells, mediators, enzymes and maybe infectious 
agents are involved. The genes that are implicated in the patho-
genesis of COPD are involved in proteolysis and antiproteolysis 
(Shapiro and Senior 1999; Stockley 2001), oxidants and anti-
oxidants (MacNee 2000), inﬂ  ammation (O’Donnell et al 2006), 
metabolism of toxic substances, airway hyperresponsiveness, 
mucus homöostasis and host defense mechanisms (O’Donnell 
et al 2006). Figure 1 show a graphical depiction of cells and 
mediator systems involved in COPD pathogenesis.
Reactive oxygen species (ROS) are induced as a direct 
result of cigarette smoke inhalation and/or increased production 
by activated inﬂ  ammatory cells and activation of the xantine 
oxidase pathway. These oxidants may inhibit by anti-oxidative 
enzymes, such as α1-antitrypsin. Parenchymal damage may be 
due to several mechanisms, including oxidative stress, inﬂ  am-
mation and apoptosis of vascular endothelial cells.
Numerous candidate genes have been studied in COPD 
case-control association studies and several candidate genes 
have been reported to be signiﬁ  cantly associated with 
COPD phenotypes (see Table 1). However, the evidence 
supporting these associations have been inconsistent in most 
of the cases due to failure in replication by other studies. 
The inconsistent replication might be due to the study 
populations (differences in phenotype deﬁ  nition, control 
subjects or COPD subtypes and/or racial differences), 
population stratiﬁ  cation, multiple testing, random error or 
small case numbers. However, combination of different 
study methods, as performed in recent studies, seems to 
provide more replicatable results. This review will focus 
on some candidate genes and recent data.
Proteolysis and antiproteolysis
α1-antitrypsin
Severe alpha1-antitrypsin (AAT) deﬁ  ciency is the one proven 
genetic risk factor for COPD. AAT is an acute phase protein that 
provides the major defense against neutrophil elastase. There are 
four main variants of AAT, classiﬁ  ed by their speed of move-
ment in gel electrophoresis: F = fast, M = medium, S = slow 
and Z = very slow (Fagerhol and Laurell 1970). In 1963 Laurell 
and Eriksson demonstrated that individuals with extremely low 
levels of AAT had an increased prevalence of emphysema. In 
the following time it was shown that AAT deﬁ  ciency was usu-
ally associated with the Z isoform of AAT (Kueppers et al 1964;
Eriksson 1965). The AAT variants are inherited in a co-dominant 
fashion, with the PiM allele being the wild-type and most 
prevalent. Homozygosity of the Z variant (Glu342Lys) results 
in severe AAT deﬁ  ciency due to a phenotype with reduced 
plasma AAT levels to 10% compared to normal AAT levels 
(for review see Needham and Stockley (2004)). However, the 
risk for COPD among PiMZ heterozygous at the α1-antitrypsin 
locus remains controversial. A recent meta-analysis compared 
COPD cases versus control subjects and found an increased risk 
for COPD among PiMZ subjects, whereas population based 
studies reported usually similar pulmonary function values 
(FEV1) in subjects with PiMZ and PiM (Hersh et al 2004).
Table 1 Linkage analysis: genomewide scans
Study Population  Main  results LOD  score§
Framingham Heart Study  Healthy Subjects:  Chromosome 6: FEV1 2.4
(Joost et al 2002)  1578 members of 330 families  Chromosome 21: FVC  2.6
National Heart, Lung and Blood   Healthy Subjects:  Chromosome 4: FEV1/FVC 3.5
Institute Family Heart Study  2178 members of 391 families  Chromosome 18: FEV1 2.5
(Wilk et al 2003)    Chromosome 18: FVC  2.9
Boston Early-onset Study  Patients with COPD + Pedigrees:  Chromosome 2q: FEV1/FVC 4.13
(Silverman et al 2002)  585 members of 72 families  Chromosome 12p: FEV1 3.26*
    Chromosome 19q: Chronic bronchitis  3.30*
    Chromosome 12p: Airway Obstruction  3.14*
Netherland Asthma Study  Patients with Asthma + Pedigrees:  Chromosome 2q: Pre- and   4.9/6.03**
(Postma et al 2005)  200 families  postbronchodilator FEV1%VC
§LOD  3 denotes signiﬁ  cant evidence for linkage; LOD  3 denotes suggestive evidence; *only smoker; **pre- and postbronchodilator FEV1%VC was obtained for 
chromosome 2q (2q32, LOD 4,9/6.03).International Journal of COPD 2007:2(4) 544
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Figure 1 Graphical depiction of cells and mediator systems involved in COPD pathogenesis. Oxidative stress, inﬂ  ammation and proteolysis and their opponents are the 
important components inﬂ  uencing disease pathogenesis.
There is signiﬁ  cant genotype-environment interaction between 
the Pi Type and pack years of smoking (Sandford et al 1999). 
However, this interaction could not explain the complete phe-
notype variations (Silverman et al 1992), suggesting gene-gene 
interaction and/or confounding other factors next to AAT 
deﬁ  ciency to be of importance.
Matrix metalloproteinases (MMP’s)
and tissue inhibitor of MMP’s (TIMP)
Matrix Metalloproteinases comprise a family of more than 20 
related proteolytic enzymes that play an important role in tis-
sue remodeling and repair in development and inﬂ  ammation. 
These enzymes degrade collagen, inactivate AAT and acti-
vate tumor necrosis factor-α (TNF-α). A functional SNP of 
the MMP9 gene promoter region had been studied in COPD 
and emphysema and had been associated in both, Chinese and 
Japanese populations (Minematsu et al 2001; Zhou et al 2004) 
However, this polymorphim was not associated with COPD 
in the Lung health Study (Joos et al 2002).
An insertion in the promoter region of MMP1 (G → GG, −
1607) that increases transcription of MMP1 by creating an 
additional transcription factor binding site, was negatively 
associated with rapid decline of FEV1 (Joos et al 2002), as 
well as a haplotype containing the MMP1 together with an 
MMP12 SNP (Asn357Ser) (Joos et al 2002).
There have been four tissue inhibitors of matrix metal-
loproteinases (TIMP) described, that inhibit active forms 
of MMP’s, with different afﬁ  nities to each MMP. MMP2 
is inhibited by TIMP-2 and this system seems to play an 
important role in emphysema (Ohnishi et al 1998). Two 
SNP’s of the TIMP2 gene have been associated with COPD 
in a Japanese population (Hirano et al 2001). The authors 
speculate that a linked gene may be associated with genetic 
susceptibility and probably not TIMP itself.International Journal of COPD 2007:2(4) 545
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α1-antichymotrypsin (SERPINA 3)
α1-antichymotrypsin (SERPINA3) is capable of inhibiting 
cathepsin G and mast cell chymase in a reversible fashion. 
In the SERPINA3 gene two functional SNPs have been 
associated with low α1-antichymotrypsin levels and COPD 
(characterized by airway resistance) in a Swedish population 
(Poller et al 1990, 1993). The association was not replicated 
in a Japanese Population. However, a third gene variation 
(non-synonymous mutation with affects to the signal peptide 
region) was found to be increased in the COPD group. Non 
of these polymorphims showed differences in an Italian study 
of patients with airﬂ  ow obstruction, though next to COPD, 
the patient group also included subjects with bronchiectasis 
(Benetazzo et al 1999).
Oxidative stress and antioxidants
An imbalance between oxidative noxes and antioxidants 
resulting in oxidative stress is postulated to be one of the 
important mechanisms in the development of COPD. Airway 
epithelium and lung matrix could be damaged by oxidative 
stress and enhance lung inﬂ  ammation with up-regulation 
of pro-inﬂ  ammatory cytokines (MacNee 2000). Cigarette 
smoke is a major source of free radicals, nitric oxide and other 
oxidants. Moreover, during inﬂ  ammatory processes radicals 
are released by leucocytes, that are known to be increased 
in the lung of patients with COPD. The lung is protected by 
antioxidative enzymes, including gluthathione-S-transferase, 
superoxide dismutase and catalase (Young et al 2006). There-
fore, functional genetic variants may be of importance by 
altering antioxidative capacity of the lung.
Glutathione-S-transferase (GST)
The family of glutathione-S-transferase comprises enzymes 
that can detoxify some noxes of tobacco smoke. There are 
functional polymorphisms, including one SNP in GSTP1 
(A313G → Ile105Val) and three alleles of GSTM1 each 
affecting enzyme activity.
The 105Ile variant of the GSTP1 gene was associated 
with airﬂ  ow obstruction in a Japanese population and with 
rapid decline of FEV1 as well as low baseline lung function 
in the Lung Health Study (He et al 2002; He 2004).
The GSTM1 alleles include one null allele, having no 
detectable GSTM1 activity in case of homozygosity. This 
genotype had been previously linked to emphysema and 
COPD (Baranova et al 1997; Harrison et al 1997). However, 
there are negative studies concerning airﬂ  ow obstruction 
and rapid decline in lung function (Yim et al 2000; He 
et al 2002).
Superoxide dismutase (SOD)
Superoxide dismutase belongs to three superoxides that can 
scavenger reactive oxygen species (ROS). They are part of the 
protection system of the lung, particularly during inﬂ  ammation. 
A functional SNP (C760G) in the SOD3 gene was found to have 
a protective effect in Caucasian COPD populations (Juul et al 
2006; Young et al 2006), probably dependent on gene-smoking 
interaction, as the genetic variant of the SOD3 gene may confer 
protection from adverse affects of cigarette smoke.
Microsomal epoxide hydrolase
Microsomal epoxide hydrolase (mEH) is expressed in human 
bronchial epithelial cells and detoxify highly reactive inter-
mediates present in cigarette smoke (Bartsch et al 1992). 
There are two functional polymorphisms that affect enzyme 
activity that account for a modest change in activity level. For 
individuals carrying both His variants (exon3: Tyr113His; 
exon4: His139Arg) a higher risk for development COPD and 
emphysema were demonstrated (Yoshikawa et al 2000). SNPs 
in the microsomal epoxide hydrolase (mEH) gene have been 
associated with severe COPD cases, emphysema and COPD 
phenotypes (Smith and Harrison 1997; Koyama and Geddes 
1998; Yoshikawa et al 2000; Park et al 2005), as well as with 
rapid decline in FEV1 in smokers (Sandford et al 2001; He 
et al 2002). However, the association failed to be replicated 
in a Corean population (Yim et al 2000).
Inﬂ  ammation and inﬂ  ammatory 
mediators
COPD is characterized by chronic airﬂ  ow obstruction due to 
chronic inﬂ  ammation based on an abnormal inﬂ  ammatory 
response (Celli and MacNee 2004). Different mediators and 
cells have been implicated in the pathogenesis of COPD, 
including TNFα, IL8 and TGF-ß. This extends beyond the 
lung to systemic manifestations, with circulating mediators 
and/or cytokines in patients serum (Sevenoaks and Stockley 
2006). Cigarette smoke activates macrophages to release 
TNF-α, LTB4, IL-8 and other neutrophil chemotactic fac-
tors, as well as antiproteases. TNF-α promotes further IL-8 
release from other cells in the respiratory tract by NF-κB 
mediated effects on gene transcription. This increases local 
neutrophilic inﬂ  ammation, and hence the release of proteases. 
Epithelial cells also stimulate ﬁ  broblasts via TGFß, a key-
player in the pathogenesis of ﬁ  brosis.
Tumor necrosis factor – alpha (TNF-α)
There is one SNP in the promoter region of the TNF-α gene, 
that is known to be functional by directly affecting gene International Journal of COPD 2007:2(4) 546
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regulation (Wilson et al 1997). Heterogeneity of study results 
demonstrate a relevance for the SNP – 308 in Asian but not 
in Caucasian populations, as in Taiwanese and Japanese col-
lectives there is an increased prevalence in COPD compared 
to controls (Huang et al 1997). Additionally, airﬂ  ow obstruc-
tion without chronic bronchitis, and severity of emphysema 
had been associated with this polymorphism in Japanese 
subjects (Sakao et al 2001, 2002). However, these results 
could not be conﬁ  rmed in Caucasian collectives (Sandford 
et al 2001; Hersh et al 2005; Seifart et al 2005), maybe due 
to variation in genotype frequencies between races, or by 
linkage disequilibrium with HLA alleles, seen previously in 
the Caucasian population (Wilson et al 1993).
Transforming growth factor-beta (TGFß)
TGFß regulates extra-cellular matrix production, cell growth 
and differentiation, tissue repair and some immune responses 
(Blobe et al 2000). Animal experiments suggests that disordered 
activation of TGFß relates to the pathogenesis of COPD.
Two recent studies, with new study designs using a 
combination of different methods, strongly suggests TGFß1 
to be of importance for COPD phenotypes. On the basis 
of the linkage analysis in the Boston Early-Onset COPD 
study that revealed suggestive linkage between an area on 
chromosome 19q – containing the TGFß1 gene – and FEV1 
(Celedon et al 2004), TGFß was genotyped in subjects of 
the Boston Early-Onset COPD study. Out of ﬁ  ve, three 
SNPs, one in the TGFß1 promotor region and two SNPs 
in the 3’ genomic region of TGFß1, had been signiﬁ  cantly 
associated with pre- and post-bronchodilator FEV1. Again, 
among 304 cases from the National Emphysema Treatment 
Trail (NETT) and smoking controls, this association was 
replicated for two of the SNPs (Hersh et al 2006), who 
linked them both to subjective measures of dyspnoea, 
though not objective exercise capacity. This apparent 
discordance may be important when deﬁ  ning phenotypes 
within COPD. The latter two SNPs have an effect on 
TGFß1 levels, as the one in the promoter region C-509T 
enhances promoter function, thus increasing levels of TGFß 
(Grainger et al 1999). While the second is a C - T change 
at position 613, that leads to an amino acid substitution 
(Leu - Pro) and higher production of TGFß1 (Suthan-
thiran et al 2000). If both of these SNPs are implicated in 
COPD subjects, it suggests that TGFß may have a protec-
tive role.
Recently, the Pro allele was found to be less common in 
COPD subjects relative to resistant smokers (OR: 0.59, p = 0.01) 
and controls (OR: 0.62, p = 0.005) (Wood and Stockley 2006).
Vitamin D binding protein
Vitamin D binding protein is a precursor of macrophage 
activating factor (MAF) and increases the neutrophil 
chemotactic properties of different peptides. This function 
could be prevented by neutrophile elastase inhibitors point-
ing out to a potential relationship between the protease-
antiprotease pathway and inﬂ  ammation.
Two non-synonymous SNPs had been identiﬁ  ed in the 
Vitamin D binding protein (GC2 and GC1S alleles), with 
the GC2 allele seemed to be protective in studies of Cau-
casian subjects (Horne et al 1990; Schellenberg et al 1998). 
The GC1S allele has not been shown to have a signiﬁ  cant 
association with COPD.
The GC1F allele has been associated with an increased 
risk of developing airﬂ  ow obstruction, emphysema and rapid 
decline of FEV1 in Japanese subjects. However, the results 
for homozygous individuals concerning an increased risk of 
developing COPD in Caucasian populations are conﬂ  icting 
(Horne et al 1990; Schellenberg et al 1998). Furthermore, 
the allele failed to be linked to rapid decline in lung function 
(Sandford et al 2001). The study heterogeneity might be due 
to difference in allele frequency between the racial groups.
Interleukin 13
Mice overexpressing IL-13 develop cathepsine and matrix 
metalloproteinase dependent emphysema (Zheng et al 2000).
A functional polymorphism in the promoter region 
(C-1055T) of the IL-13 gene leads to increased IL-13 pro-
duction (van der Pouw Kraan et al 1999). The T allele had 
been demonstrated to be more common in COPD patients 
(van der Pouw Kraan et al 2002), but this association has not 
been replicated yet.
Surfactant and SERPINE2
Surfactant
Surfactant proteins are important for normal lung function and 
play a role in the innate host defense and control of inﬂ  amma-
tion in the lung. Genetic heterogeneity of the surfactant proteins 
may explain protein and mRNA content in the lung.
Surfactant protein B is important for the formation of 
the active surfactant surface ﬁ  lm (Schurch et al 1998) and 
is essential for normal lung function (Robertson et al 1991). 
SP-B knock out mice show disruption of surfactant ﬁ  lm and 
function and die from respiratory failure (Clark et al 1995, 
1997). Furthermore, those mice are more susceptible to 
oxidative lung injury (Tokieda et al 1999).
A gene variation within intron 4 of the surfactant protein 
B (SP-B) gene had been associated with respiratory failure in International Journal of COPD 2007:2(4) 547
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COPD (Seifart et al 2002). One of the known SNPs (B1580 
C/T = Thr131Ile) in the SP-B gene was associated with COPD in 
the Boston Early-Onset study and was conﬁ  rmed in a following 
family study (Hersh et al 2005). The same polymorphism, had 
been previously associated as a smoking dependent risk factor in 
a case-control study in a Mexican population (Guo et al 2001). 
When gene-environment interaction was taking into account, 
the same polymorphism was associated with dyspnoea score and 
exercise capacity in the NETT cohort (Hersh et al 2006). Thus, 
surfactant protein B polymorphisms seemed to be of importance 
in the genetic background of COPD, probably especially in fact 
of gene-smoking or gene-environment interaction.
SERPINE 2
Prior linkage analysis in the Boston Early Onset COPD study 
demonstrated signiﬁ  cant linkage of a region on chromosome 
2q with COPD. Candidate gene selection in this region were 
done by integration of the linkage results with results from 
murine lung development and gene-expression studies of 
human COPD tissue (Demeo et al 2006). This procedure 
identiﬁ  ed SERPINE2 as a positional candidate susceptibility 
gene for COPD. Signiﬁ  cant association of 18 SNPs in the 
SERPINE2 gene with COPD phenotypes were demonstrated 
in a family-based study, while ﬁ  ve of these could be con-
ﬁ  rmed in a case control analysis with cases from the National 
Emphysema Treatment Trail.
SERPINE2 is known to be an inhibitor of thrombin, 
urokinase and plasmin. There are no studies investigating a 
separate different function of SERPINE2 in the lung so far. 
Nevertheless, SERPINE2 is postulated to be a COPD – sus-
ceptibility gene that is likely inﬂ  uenced by gene-by-smoking 
interaction (Demeo et al 2006).
Recent study approach
There are recent studies combining several study methods 
analysing candidate gene to obtain more reliable data. This 
include the combination of family-based and case-control 
studies, emerging data from linkage analysis to identify pos-
sible candidate genes and including DNA microarray data 
(Celedon et al 2004; Hersh et al 2005; Demeo et al 2006; 
Hersh et al 2006a, 2006b).
Hersh et al (2005) genotyped selected candidate genes 
previously reported to be important in COPD in a family based 
study, followed by a case-control study. Only one polymor-
phism in the surfactant protein B gene (SFTPB Thr131Ile) 
and one in the heme oxygenase gene were replicated across 
both studies. A similar approach was used in 80 markers in 22 
positional or biological plausible candidate genes with exact 
phenotype deﬁ  nition including COPD related phenotypes. 
The analysis revealed SNPs in the epoxide hydrolase, latent 
transforming growth factor ß binding protein-4 (LTBP4), 
TGF-ß1 and again SP-B to be signiﬁ  cant associated with 
COPD related phenotypes (Hersh et al 2006).
Data obtained from previous linkage analysis were used 
in two recent studies. One integrated additional results from 
gene expression proﬁ  ling (Demeo et al 2006), and both were 
followed by association analysis in a family based samples and 
a case control study. One identiﬁ  ed SERPINE2 to be a COPD-
susceptibility gene, likely inﬂ  uenced by gene-smoking interac-
tion, while the other associated TGFß1 gene variants with the 
pathogenesis of COPD among smokers (Celedon et al 2006).
Gene expression proﬁ  ling
Gene expression proﬁ  ling using cDNA microarrays may 
identify the expression of several thousand genes simul-
taneous. The method point a “photograph” of the current 
genetic activity in one tissue in comparison to another. 
Figure 2 shows graphically the principle of the method. Gene 
expression proﬁ  ling using cDNA microarrays may provide 
the possibility to identify candidate genes involved in the 
pathogenesis of emphysema, though lung tissue represents an 
end-stage picture of gene expression. Linkage of the obtained 
gene expression proﬁ  les to chromosomal regions that were 
previously associated with COPD in linkage analyses will 
focus enclose potential candidate genes. cDNA microar-
rays are capable of proﬁ  ling gene expression patterns of 
thousands of genes and/or gene clusters. It could be used to 
detect variations in transcriptional programs, including signal 
transduction and regulatory systems.
One study using microarray technology in lung tissue 
from patients with severe emphysema and controls, with one 
group of patients that had been previously diagnosed as AAT-
deﬁ  cient, showed surprisingly only modest differences between 
individuals with normal lung function and patients with end-
stage emphysema (Golpon et al 2004). However, 150 genes 
were signiﬁ  cantly different expressed between normal and 
emphysematous lung tissue samples. Expression of about 
30–50 genes differ between emphysema, emphysema due 
to AAT-deﬁ  ciency and controls, with a reduction in protein 
biosynthesis capacity as a clear characteristic of the lung 
gene expression pattern of patients with AAT deﬁ  ciency-
related emphysema. Signiﬁ  cant heterogeneity within the 
individuals of each group emphasize the multifactorial nature 
of the disease. In another study, that compares lung tissue 
of smokers with normal to mild or severe emphysema 102 
genes distinguished between the different types of smoking International Journal of COPD 2007:2(4) 548
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related lung tissue (Spira et al 2004). A total of 76 genes were 
upregulated in the lungs of smokers with severe emphysema. 
These include extracellular matrix (ECM)-related genes, 
whereas many immune and cell signaling-related genes were 
downregulated in these lungs. Overrepresented gene catego-
ries comprises ECM constituents and stress-related genes 
with oxidoreductase, isomerase, and complement activity. 
The study revealed distinct molecular subclasses of severe 
emphysema with the body mass index being the only clinical 
variable that differed between the groups.
The future
There had been some progress in the last years in genetics 
of chronic obstructive pulmonary disease. However, there 
are many areas that require more investigation. Not at least, 
epigenetic needs have to be considered.
Future genetic studies will include additional linkage 
analysis with and without combination of gene expression 
profiling. Focusing on novel phenotypes, defined by 
molecular or clinical means, will be essential in identifying 
genetic determinants for COPD. Animal model genetics 
may help in identifying several pathways of importance and 
provide more insight in some aspects of pathogenesis.
Recently, analyses using the genomewide association 
analysis approach (Hirschhorn 2005; Hirschhorn and Daly 
2005) – an aproach that involves genotyping of 300,000–
5,000,000 SNPs across the whole genome – is expected to 
provide new insights into COPD pathogenesis, though it still 
has limitations concerning statistical calculation, number of 
investigated SNPs and costs of the studies.
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